StimOxyGen
Private Company
Funding information not available
Overview
StimOxyGen is a private, pre-clinical stage biotech spin-out from Ulster University, founded in 2017 to commercialize over 15 years of academic research. The company's novel platform aims to overcome tumor hypoxia, a significant unmet clinical need that limits the success of many cancer treatments. Led by a team with strong scientific and entrepreneurial credentials, StimOxyGen is developing its lead nanoparticle program to sensitize resistant tumors to existing therapies, potentially improving outcomes for a broad range of solid tumors.
Technology Platform
pH-sensitive, oxygen-generating nanoparticles that dissolve in the acidic tumor microenvironment to provide a transient local oxygen source, sensitizing hypoxic tumors to radiotherapy, chemotherapy, and other oxygen-dependent therapies. The platform can be co-loaded with additional therapeutic payloads.
Opportunities
Risk Factors
Competitive Landscape
The competitive field includes other approaches to modulating tumor hypoxia, such as small molecule HIF-1α inhibitors (e.g., belzutifan, for specific cancers), hyperbaric oxygen, blood substitutes, and other oxygen-carrier technologies. StimOxyGen's differentiator is its localized, stimulus-responsive oxygen generation directly within the tumor via a nanoparticle, potentially offering superior targeting and fewer systemic side effects compared to broader approaches.